Histone deacetylases

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 29.10.2020

Dieser Artikel auf Deutsch

Synonym(s)

HDAC

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

Class of enzymes that induce changes in histone proteins.

General informationThis section has been translated automatically.

  • Histones play an important role in the formation of chromatin structures and in the regulation of transcription. Histones represent the protein portion of the chromatin. Acetylation and deacetylation regulate the reading of the genes on the DNA, which lies with its coils on the histones. These processes are controlled by the enzymes histone acetyltransferase and histone deacetylase (HDAC).
  • HDAC remove acetyl groups from acetylated lysine to the N-terminal histone end. Through deacetylation, the amino acid lysine regains a positive electrical charge. This increases the affinity of the histone end for the negatively charged phosphate skeleton of the DNA. The subsequent blocking of the DNA for transcription factors downregulates the DNA transcription. This is usually accompanied by the formation of inactive heterochromatin. Inhibition of histone deacetylase results in hyperacetylation of the histones. Among other things, this can cause controlled cell death (apoptosis) of the cancer cells. Normal cells are not affected by histone deacetylase inhibitors to this extent, so that a therapeutic application seems possible in this way.
  • Vorinostat is one such histone deacetylase inhibitor and has been approved by the FDA in America for the treatment of cutaneous T-cell lymphoma since October 2006. Initial studies have shown that Vorinostat is well tolerated. In a Phase II study with patients with advanced stage CTCL and described resistance to therapy, it was shown that 30 percent of patients responded to vorinostat.

LiteratureThis section has been translated automatically.

  1. Grant S et al (2007) Vorinostat. Nat Rev Drug Discov 6: 21-22
  2. Jenuwein T et al (2001) Translating the histone code. Science 293: 1074-1080

Authors

Last updated on: 29.10.2020